- DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins
- Lexaria has 16 patents granted and over 60 patent applications pending worldwide
- DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://nnw.fm/6iiPo).
Earlier this year, Lexaria moved into its new head office that includes a Health Canada licensed research and development laboratory that is being used to conduct world-leading research into drug delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://nnw.fm/WZkN8).
Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.
Cannabidiol is emerging as a promising compound to treat or prevent movement disorders, such as those seen in Parkinson’s disease patients, according to an article published by the National Institutes of Health (http://nnw.fm/VKFn9). Extending the range of drugs available for therapeutic use to treat neurological conditions such as Alzheimer’s and Parkinson’s disease is a critical area of study since there currently is no effective treatment for these diseases, according to an article in Physics World (http://nnw.fm/vA3nS).
Lexaria’s dedication to research and development can be seen in its strong and growing intellectual property portfolio. As of August 2019, the company’s patent portfolio includes approximately 60 patent applications filed and pending in more than 40 countries around the world, with 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.